Pioneering Precision Cardiovascular Medicine. (NASDAQ: MYOK) Corporate Presentation March 2018
|
|
- Dominick Golden
- 5 years ago
- Views:
Transcription
1 Pioneering Precision Cardiovascular Medicine (NASDAQ: MYOK) Corporate Presentation March 2018
2 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the clinical and therapeutic potential of mavacamten (formerly MYK-461) and MYK-491, the Company's ability to continue to advance mavacamten in the PIONEER-HCM study and MYK-491 in its Phase 1 study in healthy volunteers, the Company s expectations with respect to the release of data from these studies and the timing thereof, the Company's ability to initiate its planned Phase 3 EXPLORER-HCM study of mavacamten in symptomatic ohcm and its planned Phase 2 MAVERICK-HCM study of mavacamten in nhcm and the timing thereof, the anticipated numbers of patients expected to be enrolled in these studies, the Company s ability to initiate its planned Phase 1b trial of MYK-491 in DCM patients and generate data therefrom, and the timing of these events, as well as the requirements for registration of the Company's product candidates and the Company s projected cash runway, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the development and regulation of our product candidates, as well as those set forth in our Quarterly Report on Form 10-Q for the quarter ended December 31, 2017, and our other filings with the SEC. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. 2
3 Rethinking Cardiovascular Disease MyoKardia is applying a precision medicine approach to the discovery and development of innovative, targeted medicines for cardiovascular diseases 3
4 Company Highlights Mavacamten: Moving into Phase 3, expanding potential indications - Patient dosing in pivotal Ph 3 EXPLORER-HCM study in ohcm planned for Q Robust improvements in function and symptoms seen in Ph 2 PIONEER-HCM study - Plan to initiate PIONEER-HCM OLE in Q Ph 2 MAVERICK-HCM study in 2 nd potential indication, nhcm, expected to initiate dosing in Q MYK-491: Phase 1b underway, potential in several DCM patient subtypes - First-in-human Ph 1 study successfully completed - Ph 1b trial in DCM currently enrolling patients, topline expected in 2H Patient dosing in Ph 2 planned for 2H 2018 Discovery and Preclinical: Emerging pipeline of new targeted cardiovascular therapeutics - Applying precision medicine approach and cardiac muscle expertise - Clinical learnings informing drug discovery and preclinical programs 4
5 Other Patient Segments Mavacamten: nhcm Other Patient Segments Other Patient Segments Other Patient Segments Addressing Large Patient Populations Segmented into Smaller, Well-Defined Subgroups Total U.S. heart failure population of ~6 million Hypertrophic Cardiomyopathy (630,000) Dilated Cardiomyopathy (900,000) Obstructive HCM (410,000) Nonobstructive HCM (220,000) Genetic DCM (360,000) Idiopathic DCM (540,000) Mavacamten: Symptomatic ohcm (Orphan Drug Designation) MYK-491: Genetic DCM population(s) MYK-491: Other Targeted Indications 5 NOTE: All figures approximate. Reflect estimated diagnosed and undiagnosed totals.
6 Portfolio of Potential First-in-Class Cardiovascular Targeted Therapies Preclinical Phase 1 Phase 2 Phase 3 US rights Ex-US Mavacamten Symptomatic, obstructive HCM Non-obstructive HCM MYK-491 DCM (1) HCM-2 DCM-2 LUS-1 (1) MyoKardia retains co-commercialization option to MYK-491 in the U.S. 6 Anticipated development progress in 2018 MyoKardia Sanofi
7 Symptomatic Obstructive HCM: Our First Mavacamten Indication The ohcm Heart Autosomal dominant genetic disease Characterized by dynamic LVOT obstruction, excess contractility Thickened heart muscle is able to hold less blood and may be unable to relax Burden of Disease 65,000 of 100,000 diagnosed U.S. HCM patients have obstructive disease (1)(2) 16% diagnosis rate (3) U.S. Prevalence ~1:500 or > 630,000 (1) Chronic, progressive, debilitating Shortness of breath, chest pain, disabling heart failure, stroke Leading cause of sudden cardiac death in children and young adults Standard of Care Current disease management inadequate and not disease-specific Beta-blockers, calcium channel blockers Surgical & interventional options 7 1. AJC 2016: 100,000 patients currently seeking treatment for their HCM in the US 2. Circ 2006: 2/3 of HCM patients have obstructed disease 3. Maron et al., AJC 2016
8 Phase 2 Phase 3 Phase 2 Phase 1 Mavacamten Development Program Study Population Description Milestone SAD MAD SAD Healthy adults Safe and generally well tolerated Proof-of-mechanism achieved: reduction of cardiac hypercontractility HCM 3 Phase 1 studies completed PIONEER- HCM Cohort A PIONEER- HCM Cohort B ohcm β-blocker washout ohcm Proof-of-concept achieved: LVOT gradient reductions Improved patient symptoms across several measures Suggests starting dose and dose adjustment for Phase 3 N = 21 Treatment duration = 12 weeks Data reported Q Data reported Q EXPLORER- HCM ohcm Randomized, placebo-controlled pivotal trial to assess efficacy N = Study duration = 6 months +/- Plan to initiate patient dosing Q MAVERICK- HCM nhcm Assess safety, efficacy and determine optimal dosing N = 60 Study duration = 7 months Plan to initiate patient dosing Q PIONEER-HCM - Cohort B PIONEER-HCM Cohort A Long-Term PIONER Extension EXPLORER-HCM Planned NDA Filing Phase 1 studies Long-Term EXPLORER Extension MAVERICK-HCM 9 Today
9 PIONEER-HCM: Baseline Characteristics Largely Similar Across Dose-Ranging Cohorts Trial Design Baseline Characteristics Cohort A Cohort B Cohort A Cohort B Dose Dose adjustment criteria 10mg, 15mg, 20mg Percentage decrease in LVEF from baseline 2mg, 5mg Percentage decrease in resting LVOT gradient from baseline N Age (years) mean (min-max) 56 (22 70) 57 (22 71) Sex, % male 64% 50% NYHA Class 64% Class II; 36% Class III 50% Class II; 50% Class III Concomitant β- blockers, N (%) 0 (0) 9 (90) Mavacamten Study Drug Parameter (Mean ±SD) Cohort A Cohort B Starting Dose Adjusted Dose Resting LVEF (%) 70 ± 7 75 ± 5 Exercise LVEF (%) 76 ± 8 76 ± 8 Dose Adjustment Resting LVOT Gradient (mm Hg) Exercise LVOT Gradient (mm Hg) 60 ± ± ± ± 43 Peak VO 2 (ml/kg/min) 20.7 ± ± 4.6 9
10 Demonstrated Efficacy and Safety Across a Broad Range of Mavacamten Doses Change, from baseline to W12 Mean ± SD p-value Mean ± SD p-value Cohort A Cohort B Post-exercise LVOT gradient (mmhg) -112 ± ± Resting LVOT gradient (mmhg) -55 ± ± Resting LVEF (%) -16 ± ± NYHA class -0.9 ± ± Peak VO2 (ml/kg/min) +3.5 ± ± Dyspnea numerical rating -3.1 ± ± Additional Observations Mavacamten was generally well tolerated - Most AEs were mild (80%) to moderate (19%) - Most AEs were deemed unrelated to mavacamten (79%) Effect of Beta Blockers No discernable impact on mavacamten s pharmacodynamics profile were observed with use of background beta blockers LVOT gradient, NYHA class, LVEF measures reverted towards baseline during fourweek washout period 10
11 mmhg mmhg PIONEER-HCM: Mavacamten Reduces LVOT Gradient Cohort A Post-Exercise LVOT Gradient (p=0.002) 1 Cohort B Post-Exercise LVOT Gradient (p=0.020) 2 Patient achieving a reduction in post-exercise LVOT gradient below hemodynamic significance (< 50 mmhg): - Cohort A: 10/10 - Cohort B: 4/10 Impact of gradient on symptoms and function confirms previous literature findings 1 Heitner, et al; HFSA Jacoby, et al; ACC
12 mmhg mmhg PIONEER-HCM: Mavacamten Reduces LVOT Gradient Cohort A Resting LVOT Gradient (p=0.006) 1 Cohort B Resting LVOT Gradient (p=0.004) 2 Patient achieving a reduction in post-exercise LVOT gradient below hemodynamic significance (< 50 mmhg): - Cohort A: 10/10 - Cohort B: 4/10 Impact of gradient on symptoms and function confirms previous literature findings 1 Heitner, et al; HFSA Jacoby, et al; ACC
13 PIONEER-HCM: Consistent Improvements in Function and Symptoms Observed Across Dose-Ranges: Peak VO 2 Cohort A Baseline Week 12 Change p-value Peak VO 2 (ml/kg/min) 20.7 ± ± ± VE/VCO ± ± ± Circulatory Power (mm Hg mlo2 kg 1 min 1) 3276 ± ± ± Heitner, et al; HFSA 2017 Cohort B Peak VO 2 (ml/kg/min) Baseline Week 12 Change p-value 19.4 ± ± ± VE/VCO ± ± ± Circulatory Power (mm Hg mlo2 kg 1 min 1) 2944 ± ± ± of 10 patients had an improvement in peak VO ml/kg/min (~10% increase) - 4 of these 5 were on β-blockers 13 Jacoby, et al; ACC 2018
14 PIONEER-HCM: Consistent Improvements in Function and Symptoms Observed Across Dose-Ranges: NYHA Class NYHA Classification Cohort A Mean change -0.9 (p=0.016) - 5 subjects with 1 class improvement - 2 subjects with 2 class improvement Cohort B Heitner, et al; HFSA 2017 Mean change -1.0 (p=0.004) - 8 subjects with 1 class improvement - 1 subject with 2 class improvement Jacoby, et al; ACC
15 PIONEER-HCM: Emerging Target Mavamcamten Concentration Range will Inform Starting Dose and Dose Adjustment in EXPLORER-HCM Mavacamten Concentrations vs. Provoked LVOT Jacoby, et al; ACC
16 Pivotal EXPLORER-HCM Study to Begin Dosing in Q Study Goal: Demonstrate Clinically-Meaningful Improvements in Symptoms Population Symptomatic ohcm (similar to PIONEER-HCM) Design Randomized, double-blind, placebo-controlled Study Size Approximately patients Treatment Key Endpoints Anticipated Milestones Daily oral dosing for ~6 months Dose adjustment based on physiologic response Post-exercise LVOT gradient Change in exercise capacity (peak VO 2 ) NYHA functional class LVEF Dyspnea symptom score NT-proBNP Regulatory update Q Initiate patient dosing in Q Subject to finalization
17 Non-Obstructive HCM: Potential Second Indication for Mavacamten The nhcm Heart Same underlying genetics as ohcm Characterized by excess contractility without a physical obstruction More uniformly thickened heart muscle is unable to relax and fill with blood normally Burden of Disease Standard of Care nhcm is estimated to make up onethird of HCM population (1)(2) Patients typically diagnosed after disease progression Chronic, debilitating symptoms Shortness of breath, chest pain, disabling heart failure, stroke Lacking therapeutic options No disease-specific therapeutics Beta blockers and diuretics may be used to improve symptoms Heart transplant option of last resort Alternate surgical options unavailable AJC 2016: 100,000 patients currently seeking treatment for their HCM in the US 2. Circ 2006: 2/3 of HCM patients generally are obstructed
18 MAVERICK-HCM Phase 2 Initiating in Q Study Goal: Demonstrate Safety, Tolerability and Evidence of Activity Across Additional Endpoints Population Symptomatic nhcm with preserved LVEF Design Study Size 60 patients at 35 sites Treatment Randomized, double-blind, placebo-controlled Three-arms: mavacamten doses targeting two plasma concentrations vs. placebo Daily oral doses for 16 weeks Dose adjustment at week 6 Primary Endpoint Safety and tolerability Additional Endpoints Anticipated Milestones Exercise capacity as measured by peak VO 2 LVEF PD & PK Quality of life, daily activity NT-proBNP (rest & exercise) Reversibility Initiate patient dosing Q
19 Portfolio of Potential First-in-Class Cardiovascular Targeted Therapies Preclinical Phase 1 Phase 2 Phase 3 US rights Ex-US Mavacamten Symptomatic, obstructive HCM Non-obstructive HCM MYK-491 DCM (1) HCM-2 DCM-2 LUS-1 (1) MyoKardia retains co-commercialization option to MYK-491 in the U.S. 19 Anticipated development progress in 2018 MyoKardia Sanofi
20 Dilated Cardiomyopathy (DCM): Devastating Disease with No Approved Therapies The DCM Heart Characterized by thin walls of left ventricle and hypocontractility Inadequate contraction and insufficient blood pumped by heart Burden of Disease ~ 900,000 DCM patients in the U.S., 40% with identified gene mutation Chronic, progressive, debilitating Shortness of breath, edema, fatigue Interference with daily activities Increased risk of sudden cardiac death and need for heart transplant Standard of Care No approved therapeutics to target underlying disease Nonspecific heart failure therapies Treatments for advanced disease complex and limited in availability & efficacy LVAD, transplant, palliative care 20
21 % Change from Baseline % Change from Baseline MYK-491 Improves Cardiac Function without Impairing Relaxation in Preclinical Models MYK-491: Designed to Improve Symptoms of Heart Failure MYK-491 is a cardiac myosin activator - Heart muscle protein mutations diminish systolic contraction Targets the biomechanical cause of DCM - Inadequate motor engagement Goals of treatment - Increase the extent of contraction - Minimal impact on diastole / relaxation - Potential for beneficial remodeling - Potential wider therapeutic index Preclinical Data Paced HF Dog Model LVOT-Velocity Time Integral Vehicle 1 mg/kg 3 mg/kg 5 mg/kg 0h 3h 6h Tau (Time Constant of Isovolumic Relaxation) Vehicle 1 mg/kg 3 mg/kg 5 mg/kg h 3h 6h 20
22 MYK-491 First-in-Human Safety Study Complete Study Goal: Demonstrate Tolerability, Inform Starting Dose for Ph 1b Phase 1 Clinical Trial of MYK-491 Design Population Endpoints Randomized, double-blind, placebo controlled Single ascending dose 64 healthy volunteers 48 subjects received 16 subjects received placebo Safety, tolerability, PK, PD Echocardiographic measures of effect on contractility Topline Results MYK-491 was well tolerated - Adverse events were benign and transient Increases in contractility observed at highest dose cohorts Phase 1b starting dose identified 22
23 MYK-491 Phase 1b in DCM Patients Underway Study Goal: Demonstrate Proof-of-Mechanism in Patients Design Phase 1b Randomized, double-blind, placebo controlled, Adaptive design Single ascending dose Population DCM patients with stable, moderate HF Endpoints Anticipated Milestones Safety, tolerability, PK, PD Echocardiographic measures of effect on contractility Results anticipated in 2H
24 Portfolio of Potential First-in-Class Cardiovascular Targeted Therapies Preclinical Phase 1 Phase 2 Phase 3 US rights Ex-US Mavacamten Symptomatic, obstructive HCM Non-obstructive HCM MYK-491 DCM (1) HCM-2 DCM-2 LUS-1 (1) MyoKardia retains co-commercialization option to MYK-491 in the U.S. 24 Anticipated development progress in 2018 MyoKardia Sanofi
25 Research Focus: Cardiac Muscle Contraction and Relaxation Cardiomyopathies Result from 3 Types of Cardiac Muscle Disruptions Normal Heart Hypertrophic Cardiomyopathy (HCM) Dilated Cardiomyopathy (DCM) Normal contraction Excessive contraction Impaired relaxation Inadequate contraction 25
26 Targeting Cardiac Muscle Proteins to Modulate Function Mavacamten and MYK-491: Myosin-actin cross bridge Myosin binding Myosin-actin protein C crossbridge Troponin α Tropomyosin T Troponin I Actin Pipeline programs: Validated genetic targets Myosin light chain β Myosin heavy chain 26
27 Integrated, Disease-Focused Approach Generating New Leads & Advancing to INDs Precision Medicine Research Select disease targets in causal pathway Identify patient populations most likely to benefit Physician/Patient Initiatives SHaRe HCM Cares App Affairs of the Heart events Symptoms and function endpoints Imaging biomarkers Digital health wearable Diagnosis Monitoring Clinical Experience 27
28 2018 Multiple Value-Creating Clinical Milestones 2018 Q Initiate MAVERICK- HCM study in nhcm Q Report data from PIONEER-HCM Cohort B Q Report data from Phase 1 study in healthy volunteers Q Initiate Phase 3 EXPLORER-HCM study Q Initiate PIONEER Open-label Extension 2H 2018 Preclinical & Discovery-stage Pipeline Update 2H 2018 Report data from Phase 1b in DCM patients 2H 2018 Initiate Phase 2 study for MYK-491 Mavacamten Milestone MYK-491 Milestone Q Initiate Phase 1b patient study Well resourced to execute Cash and investments as of Q = $276M Anticipate current cash + potential Sanofi payments will fund operations into
29 Thank You 29
30 The Obstructed HCM Heart Characterized by dynamic LVOT obstruction, excess contractility Thickened heart muscle is able to hold less blood and may be unable to relax HCM CARE 30
31 PIONEER-HCM (Cohort B): Low Doses of Mavacamten Lead to Clinically Meaningful Results While Preserving LVEF Change in resting LVEF Jacoby, et al; ACC
Cohort A. Number of patients
MyoKardia Announces Positive Results from Low- Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients Met Primary Endpoint and Key Secondary
More informationPIONEER-HCM Cohort B Results:
PIONEER-HCM Cohort B Results: Reduction in left ventricular outflow tract gradient with mavacamten in symptomatic obstructive hypertrophic cardiomyopathy patients D Jacoby 1, S Lester 2, A Owens 3, A Wang
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationCapricor Therapeutics
Therapeutics Conference Call to Discuss the HOPE-2 Clinical Trial NASDAQ: CAPR November 29, 2017 Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationSelective Cardiac Myosin Activators in Heart Failure
Selective Cardiac Myosin Activators in Heart Failure John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationAM-125 : Intranasal Betahistine
AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationDefined by Science Powered by Innovation Inspired by Patients
CYTOKINETICS ANNUAL STOCKHOLDER MEETING MAY 22, 2013 1 Forward-Looking Statements 2 Statements in and/or made by our representatives in connection with this presentation regarding future events or our
More informationPROMISE 1 Top-Line Data Results. June 27, 2017
PROMISE 1 Top-Line Data Results dd June 27, 2017 Forward Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationFebruary 20, 2019 MANAGEMENT CALL TO DISCUSS PHASE 2 PHOENIX RESULTS AND CKD PROGRAM UPDATES
February 20, 209 MANAGEMENT CALL TO DISCUSS PHASE 2 PHOENIX RESULTS AND CKD PROGRAM UPDATES Forward-Looking Statements This presentation contains certain forward-looking statements that are made pursuant
More informationSAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018
SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical
More informationUtrophin Modulation: A Universal Treatment Approach to DMD. End Duchenne Tour April 2018
Utrophin Modulation: A Universal Treatment Approach to DMD April 2018 Legal Disclaimer Statements in this presentation, other than statements of historical fact, constitute forward-looking statements within
More informationUSPSTF Draft Recommendations Investor Call. October 6, 2015
USPSTF Draft Recommendations Investor Call October 6, 2015 v Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the
More informationRevolutionizing how advanced heart disease is treated. Alexei Marko, CEO Chris Clark, CFO November 2014
Revolutionizing how advanced heart disease is treated Alexei Marko, CEO Chris Clark, CFO November 2014 Forward-Looking Statements Statements contained herein that are not based on historical or current
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More informationKeyzilen TM Program Update
Keyzilen TM Program Update October 11, 2016 Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial risks and uncertainties.
More informationSTUDY 1 PHASE 3 TOP-LINE RESULTS. September 2017
STUDY 1 PHASE 3 TOP-LINE RESULTS September 2017 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationRevolutionizing how advanced heart disease is treated
LEERINK Partners 5th Annual Healthcare Conference Revolutionizing how advanced heart disease is treated NASDAQ: NCVN, TSX: NVC Alexei Marko, CEO February 2016 Forward-Looking Statements Statements contained
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationmicrorna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease
microrna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease January 2018 Safe Harbor Statement Statements contained in this presentation regarding matters that are not
More informationXP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED.
XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. SAFE HARBOR DISCLAIMER These slides and the accompanying oral
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationFirst-in-Class Treatment for Hyperinsulinemic Hypoglycemia. January 31, 2017
358 First-in-Class Treatment for Hyperinsulinemic Hypoglycemia January 31, 2017 Forward-Looking Statement Certain statements contained herein including, but not limited to, expected licensing transactions,
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationZogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008
More informationREATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS
REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS IRVING, Texas August 8, 2018 Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationAquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC. August 6, 2015
Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC August 6, 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary
More informationRest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome
Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome G. Deswarte, AS. Polge, N. Lamblin, A. Millaire, M. Richardson, C. Bauters,
More informationMay 10, 2016 Q & Business Update
May 10, 2016 Q1 2016 Thank Financial you Results & Business Update Q1 2016 Financial Results Prepared Remarks Q1 Update Tom Hughes, Ph.D., Chief Executive Officer Clinical Update Dennis Kim, M.D., Chief
More informationProthena Corporation plc Overview
November 11, 2014 Prothena Corporation plc Overview 2014 Credit Suisse HC Conference The Arizona Biltmore Phoenix, AZ Forward-Looking Statements This presentation contains forward-looking statements. These
More informationTreatment of Hypertrophic Cardiomyopathy in Bruce B. Reid, MD
Treatment of Hypertrophic Cardiomyopathy in 2017 Bruce B. Reid, MD Disclosures I have no conflicts of interest to disclose I will not be discussing any off label medications and/or devices Objectives 1)
More informationNorthera (droxidopa) Preliminary Findings From Study 301 in Symptomatic Neurogenic Orthostatic Hypotension. September 2010
Northera (droxidopa) Preliminary Findings From Study 301 in Symptomatic Neurogenic Orthostatic Hypotension September 2010 1 2004-2010 Chelsea Therapeutics, Inc. This presentation is being provided for
More informationNovember 2, Q Financial Results
November 2, 2017 Q3 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationProsensa Corporate Overview Jefferies Healthcare Conference London, UK November 19, Hans Schikan, CEO
Prosensa Corporate Overview Jefferies Healthcare Conference London, UK November 19, 2014 Hans Schikan, CEO Forward-Looking Statements This presentation may contain statements that constitute forward-looking
More informationInvestor Overview. March 2019
Investor Overview March 2019 Forward-Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as may, might, will,
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationΔυναμική υπερηχοκαρδιογραφία στις μυοκαρδιοπάθειες : έχει θέση και ποια ;
Ελληνική Καρδιολογική Εταιρεία Σεμινάρια ομάδων εργασίας Θεσσαλονίκη, 8-10 Φεβρουαρίου 2018 Ομάδα εργασίας Ηχωκαρδιολογίας Δυναμική υπερηχοκαρδιογραφία στις μυοκαρδιοπάθειες : έχει θέση και ποια ; ΑΓΑΘΗ-ΡΟΖΑ
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationLJPC-401 Phase 1 Results and Development Update. September 7, 2016
LJPC-401 Phase 1 Results and Development Update September 7, 2016 Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationCorporate Presentation August 6, 2015
Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationPROMISE 2 Top-Line Data Results January 8, 2018
PROMISE 2 Top-Line Data Results January 8, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationMedical Policy and and and and
ARBenefits Approval: 10/12/2011 Effective Date: 01/01/2012 Revision Date: Code(s): 93799, Unlisted cardiovascular service or procedure Medical Policy Title: Percutaneous Transluminal Septal Myocardial
More informationACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST
ACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST Investor Webcast July 2016 Copyright The following information contains certain forward-looking statements, relating to the company s business, which can
More informationBio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with
More informationSAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines
SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and
More informationOxurion NV Business Update Q End Q cash position 95.1 million
Oxurion NV Business Update Q3 2018 Shareholders Approval and Launch of Oxurion NV as new Company Name First patient enrolled in Phase 1 study evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for
More informationInvestor Presentation March 2015
Investor Presentation March 2015 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationCorporate Presentation Asia Investment Series March 2018
Corporate Presentation Asia Investment Series March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United
More informationInnovative Therapeutics for Orphan Liver Disease
Innovative Therapeutics for Orphan Liver Disease Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements within the meaning of the Securities
More informationCreating a Leading Global HBV Therapeutics Company. ARB-1467 Update Call December 12, 2016
Creating a Leading Global HBV Therapeutics Company ARB-1467 Update Call December 12, 2016 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking statements
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationDelivering Innovation. Where It s Needed. August 2018
Delivering Innovation. Where It s Needed. August 2018 Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements within the meaning of the Securities Act of
More informationProthena Corporation plc
Prothena Corporation plc PRX003 Investor Update: Phase 2 Development Strategy September 29, 2016 Agenda Dr. Gene Kinney, Chief Operating Officer Introduction Dr. Ken Flanagan, Senior Scientist Th17 and
More informationHeart Failure Overview. Dr Chris K Y Wong
Heart Failure Overview Dr Chris K Y Wong Heart Failure: A Growing, Global Health Issue Heart Failure 23 Million Afflicted Global Impact Worldwide ~23 million peopleworldwide afflicted with CHF 1 Exceeds
More informationDiscovery of Potent, Highly Selective, Broad Spectrum Antivirals
Discovery of Potent, Highly Selective, Broad Spectrum Antivirals Fred Hutch/Merck Infectious Disease Summit May 10, 2018 Sam Lee, Ph.D. 1 Forward Looking Statements This presentation contains forward-looking
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Investor Presentation March 2017 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking
More informationPhase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018
Phase 3 investigation of aprocitentan for resistant hypertension management Investor Webcast June 2018 The following information contains certain forward-looking statements, relating to the company s business,
More informationQ3 18 Earnings Supplemental Slides
(Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More informationPimavanserin Top-Line Results Phase III Parkinson s Disease Psychosis Trial (-020 Study) Creating the Next Generation of CNS Drugs
Pimavanserin Top-Line Results Phase III Parkinson s Disease Psychosis Trial (-020 Study) Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements.
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationNeedham Healthcare Conference. April 10, 2019
Needham Healthcare Conference April 10, 2019 Forward-Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the safe harbor
More informationMachine Learning Detection of Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor
Machine Learning Detection of Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor AHA 2017 Late Breaking Basic Science Eric M. Green MD, PhD, Reinier van Mourik PhD, Charles Wolfus JD, Stephen
More informationSavient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference EAST BRUNSWICK, N.J., Oct 27, 2008 /PRNewswire-FirstCall
More informationNew Ideas. Better Medicines. Third Quarter Financial Results Conference Call
New Ideas. Better Medicines. Third Quarter 2018 Financial Results Conference Call Forward-Looking Statements 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties.
More information35 th Annual J.P. Morgan Healthcare Conference
35 th Annual J.P. Morgan Healthcare Conference Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's
More informationUBS Global Healthcare Conference May 19, 2014
UBS Global Healthcare Conference May 19, 2014 Safe Harbor Statement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationZafgen PWS Clinical Trial Program Overview. November 16, 2014
Zafgen PWS Clinical Trial Program Overview November 16, 2014 2 Disclaimers Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information.
More informationBuilding a Stroke Portfolio. June 28, 2018
Building a Stroke Portfolio June 28, 2018 1 Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to: the potential benefits, safety and efficacy
More informationNovel Medicines for Life-Altering CNS Disorders
Novel Medicines for Life-Altering CNS Disorders November 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forwardlooking statements, which may be identified by
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationJefferies Healthcare Conference. June 25, 2008
Jefferies Healthcare Conference June 25, 2008 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationASCEND Phase 2 Trial of AXS-05 in MDD Topline Results Conference Call
NASDAQ: AXSM ASCEND Phase 2 Trial of in MDD Topline Results Conference Call January 7, 2019 Overview in MDD ASCEND Phase 2 Trial Topline Results Introduction Mark Jacobson, Senior Vice President, Operations
More informationSteel vs Alcohol. Or Neither. Management of Hypertrophic Cardiomyopathy. Josh Doll, MD January 24, 2015
Steel vs Alcohol Or Neither Management of Hypertrophic Cardiomyopathy Josh Doll, MD January 24, 2015 47yo Male, Mr. L Severe progressive dyspnea on exertion and weight gain Previous avid Cross-Fit participant
More information2011 HCM Guideline Data Supplements
Data Supplement 1. Genetics Table Study Name/Author (Citation) Aim of Study Quality of life and psychological distress quality of life and in mutation psychological carriers: a crosssectional distress
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life
Breathtaking science Developing respiratory drugs to improve health and quality of life June 2017 Forward-Looking Statements This presentation contains forward looking statements that are based on the
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Jefferies Global Healthcare Conference June 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking
More information-- Single Global Phase 3 Trial Expected to Begin in First Half of
Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment -- Consistent
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationWe strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis
Nivalis Therapeutics, Inc., October 2015 Analyst Breakfast at NACFC We strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis Disclaimer Regarding Forward
More informationGW Pharmaceuticals plc. Investor Presentation August 2014
GW Pharmaceuticals plc Investor Presentation August 2014 Forward Looking Statements and Disclaimer This presentation contains forward-looking statements. Some of the matters discussed concerning our operations
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationInfluence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy
ORIGINAL ARTICLE 5 RAAS inhibitors should be avoided if possible in patients with obstructive HCM Influence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy Katrin Witzel,
More informationPathophysiology: Heart Failure
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions
More information